Global Disitamab Vedotin Market Strategic Research Report

Scope of the Report

The global Disitamab Vedotin market size is predicted to grow from US$ 313 million in 2025 to US$ 1,185 million in 2032; it is expected to grow at a CAGR of 17.9% from 2026 to 2032.

Disitamab Vedotin is an antibody–drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It consists of a humanized anti-HER2 monoclonal antibody, a cleavable linker, and a cytotoxic microtubule inhibitor payload. The antibody component specifically recognizes HER2-expressing tumor cells and delivers the cytotoxic agent into the cells, where the active component is released to inhibit microtubule polymerization and induce tumor cell apoptosis. This drug is mainly used for the treatment of various HER2-expressing solid tumors, such as gastric cancer and urothelial carcinoma. It is characterized by strong targeting specificity, significant efficacy, and manageable toxicity, making it an important innovative therapy in the field of HER2-targeted treatmentsIn 2025, global production of disitamab vedotin (RC48, trade name: Aidixi®) reached approximately 320,000 units.

Disitamab Vedotin, as a HER2-targeting antibody–drug conjugate (ADC), is currently in a rapid growth phase within the precision oncology market. With the expanding patient population of HER2-expressing tumors such as gastric cancer and urothelial carcinoma, along with increasing HER2 testing rates, the target population for this drug continues to grow, driving sustained market demand. Meanwhile, the maturation of ADC technology platforms and the accumulation of clinical data have led to increasing recognition of its efficacy and safety, enhancing its market competitiveness. However, competition is also intensifying, including from global blockbuster ADC products such as Enhertu as well as other HER2-targeted therapies, which pose direct competitive pressure. Overall, the market for Disitamab Vedotin represents a “high-value, high-growth” segment, with future expansion mainly driven by indication expansion, development in HER2-low populations, and global commercialization efforts.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Disitamab Vedotin market?

What factors are driving Disitamab Vedotin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Disitamab Vedotin market opportunities vary by end market size?

How does Disitamab Vedotin break out by Type, by Application?

This report presents a comprehensive overview of the global Disitamab Vedotin market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Monoclonal Antibody, mAb
• Polyclonal Antibody, pAb
• Bispecific Antibody, bsAb

Segment by Strength

• 60 mg/vial
• 120 mg/vial

Segment by Production Technology

• Originator
• Generic

Segment by Dosage Form

• Lyophilized Powder for Injection
• Injection Solution

Segment by Application

• Gastric Cancer
• Urothelial Carcinoma (UC)
• Breast Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Disitamab Vedotin market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Gastric Cancer, Urothelial Carcinoma (UC), Breast Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact